Korea orders inspections of clinics over obesity injection sales that bypass pharmacies

South Korea's health ministry will inspect clinics suspected of illegal obesity injection sales that bypass pharmacies. The Ministry of Health and Welfare said on October 22 that it would carry out on-site checks with local governments at medical institutions that receive the largest supplies of self injected obesity drugs. Korean law requires doctors to prescribe these medicines and pharmacists to dispense them. The ministry said cases of clinics selling large amounts directly to patients, without giving the injections themselves, had risen sharply.

What the ministry announced

The announcement came from the ministry's pharmaceutical policy division. It covers self injectable obesity drugs, which are prescription medicines designed for patients to inject at home. Under the Pharmaceutical Affairs Act, these products must reach patients through a doctor's prescription and a pharmacist's dispensing, a split that Korea calls the separation of prescribing and dispensing. There is one exception. A clinic may supply and inject the drug itself when it is teaching a patient how to inject and gives the injection on site. The ministry said it had repeatedly reminded medical institutions of that limit, yet some were now selling considerable quantities without injecting anything at all.

The checks will focus on institutions with the highest supply volumes nationwide where on-site dispensing and sales are suspected, according to the ministry press release. Officials will verify compliance and take action under the relevant laws when they find violations. Under the Pharmaceutical Affairs Act, breaking the prescribing and dispensing rule is punishable by a prison term of no more than one year, or a fine capped at 10 million won. Failing to issue a prescription can also lead to a 15 day licence suspension for a first offence and a 30 day suspension for a second within two years under the Medical Service Act. The ministry said it will keep tracking supplies to individual institutions after the inspections end.

Why obesity injection sales drew scrutiny

The ministry did not name specific products, but the self injected obesity drugs on the Korean market are GLP 1 based peptides such as semaglutide, sold as Wegovy, and tirzepatide, sold as Mounjaro. Demand has grown quickly. "Demand for self-injectable obesity drugs is increasing, but this must not lead to illegal drug sales that circumvent the separation of prescribing and dispensing," Kwak Soon-heon, the ministry's director general for health care policy, said, in the translation published by Korea Biomedical Review. He said oversight would be strengthened to protect public health and prevent misuse. The ministry did not say how many clinics will be visited or when the checks will start.

The ministry did not name specific products, but the self injected obesity drugs on the Korean market are GLP 1 based peptides such as semaglutide, sold as Wegovy, and tirzepatide, sold as Mounjaro.

The inspections follow other signs of loose control over these drugs in Korea. Data from the Health Insurance Review and Assessment Service, released by lawmaker Seo Young-seok of the Democratic Party of Korea, showed that doctors went ahead with GLP 1 obesity prescriptions despite duplicate use alerts in 70,018 cases between October 2024 and August 2026, Korea Biomedical Review reported. The alerts fire when a patient already holds a prescription for the same ingredient from another institution, but they are advisory. Tirzepatide accounted for 23,321 such cases in the first eight months of 2026, up from 3,332 in 2025. The national system does not warn about overlapping prescriptions of different obesity drugs.

How Korea fits a wider pattern

Regulators in several countries are trying to keep obesity peptides inside normal medical channels as demand outruns oversight. Japan's health ministry recently recirculated its rules on appropriate use with a ketosis warning for slimming use, aimed at clinics prescribing the drugs outside approved indications. Korea's step is different in kind. It does not question whether patients should receive the drugs, but how the drugs reach them. Direct sales by clinics remove the pharmacist from the chain, which means one less check on duplicate prescriptions, storage and counselling about side effects. That gap matters more as more of these products reach the Korean market.

Elsewhere the concern centres on products that never enter the regulated chain. In Iceland, pharmacies have reported rising insulin syringe sales as unregulated peptides spread, and customs tests found seized vials often did not match their labels. Korea's inspections address an earlier point in the chain: approved drugs supplied by licensed clinics outside the rules. Lawmaker Seo said repeat prescriptions from several institutions raise concerns about misuse and possible resale through illegal secondhand trading. He called for obesity drugs to be added to the system's class level duplicate checks and for doctors to record why they override alerts. The ministry has not said whether it will adopt those proposals.

What comes next

The ministry said the inspections will be run jointly with local governments and that legal action will follow when violations are found. It also said supply monitoring of individual institutions will continue after the inspections, which suggests the checks are meant to change practice rather than act as a single sweep. No results have been published yet, and the ministry has not said whether it will name clinics found in breach. Patients are not the target of the checks. For people using these medicines, the practical rule is unchanged: the drug should come with a prescription and be dispensed by a pharmacy, unless a clinic is giving the injection itself.

The step comes as Korea's obesity drug market grows more crowded. Hanmi Pharmaceutical's efpeglenatide, approved by the Ministry of Food and Drug Safety on October 7 as the first obesity GLP 1 drug developed in Korea, is due to reach selected clinics around October 29, Korea Biomedical Review has reported. More products mean more supply moving through clinics and pharmacies, and the ministry's tracking of supply volumes is its main tool for spotting unusual patterns. Whether the inspections lead to penalties, and whether duplicate prescription checks are tightened, will show how far Korea intends to go in policing obesity injection sales.

Conclusion

Korea is moving to enforce the line between prescribing and dispensing for obesity injection sales, after the health ministry reported a sharp rise in clinics selling self injected drugs directly to patients. The inspections target the highest volume suppliers, with prison terms, fines and licence suspensions possible under existing law. Data showing tens of thousands of prescriptions issued despite duplicate alerts add pressure for tighter controls. The results of the checks have not yet been published.